LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a product name.
REQUEST A FREE TRIAL
Product
Deals
Articles
BioCentury
|
Feb 9, 2023
Product Development
Catalysts beyond cystic fibrosis await Vertex after $8.9B year
Along with its successor to blockbuster Trikafta in CF, the biotech is advancing a diversified pipeline encompassing pain, hematology and kidney disease
Read More
BioCentury
|
Oct 7, 2020
Deals
Roche deal for CF program brings return to Enterprise’s syndicate without full takeout
U.K. biotech sells one ion channel program, keeps another
Read More
BioCentury
|
May 25, 2020
Finance
New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more
Read More
BioCentury
|
Sep 24, 2019
Politics & Policy
Labour leader Corbyn vows compulsory licensing to slash prices of patented drugs
Read More
BioCentury
|
Sep 13, 2019
Company News
Vertex reaches CF deal in Scotland
Read More
BioCentury
|
Aug 22, 2019
Politics & Policy
Changing of the guard at NICE
Read More
BioCentury
|
Aug 12, 2019
Company News
Vertex fails to reach CF deal in Scotland
Read More
BioCentury
|
Jul 25, 2019
Company News
As Vertex broadens remit, Leiden handing baton to Kewalramani
Read More
BioCentury
|
Jun 26, 2019
Politics & Policy
NICE RWE proposal could open door to more managed access
Read More
BioCentury
|
Jun 10, 2019
Politics & Policy
MPs, health secretary more open to compulsory licensing of CF drugs
Read More
Items per page:
10
1 - 10 of 89
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help